Educational research & price index · Independent Janoshik & MZ Biolabs COA verification
Guide|3 CitationsHormonal & GH67-AA DES vs. 83-AA LR3 Blend / Stack

IGF-1 DES (1-3) Dosing Protocol: Local IGF-1 vs. IGF-1 LR3 Guide

Also known as: DES(1-3)IGF-1, Truncated 67-AA Local IGF-1 Analog, IGF-1 DES vs. IGF-1 LR3

Dose Range
20–50 mcgResearch range
0Typical research window: 20–50 mcg100 mcg

Studied in published research — not a medical recommendation. Primary protocol (Site-Specific Local / Peritendinous Research Protocol): 20–50 mcg total (split 10–25 mcg bilaterally into target tissue), Training or rehabilitation days only (3–5x/week immediately pre- or post-session).

Protocol at a Glance
How Often
Training or rehabilita

Training or rehabilitation days only (3–5x/week immediately pre- or post-session)

A Typical Run
4 weeks on, followed by 4 weeks off to prevent IGF-1R downregulation

Research-reported range (no primary dosing study). Keep fast-acting carbohydrates on hand for 45 minutes post-administration; much shorter hypoglycemia monitoring window than IGF-1 LR3

How It's Taken
Vial

Subcutaneous peritendinous or shallow intramuscular

Evidence
Clinical Trials

Published peer-reviewed research & clinical protocols

Half-Life & 72-Hour Clearance Shape
Not established

No verified human half-life on file for this compound

0h18h36h54h72h
On Your SyringeU-100 Insulin Syringe

A vial is powder until you add bacteriostatic water. Change the vial size or water volume below to see the exact unit mark on your syringe.

5 mg vial · 2 mL water · 0.3 mL syringe
Concentration: 2.5 mg in every mL (25 mcg per unit)
0u6u12u18u24u30u
Low end: 20 mcg0.8 units
High end: 50 mcg2 units

All U-100: 100 units = 1 mL. 250 doses in the vial at the low end (100 doses at the high end).

Track the doses you run

Save IGF-1 DES (1-3) to your personal protocol list to log your custom dosage, syringe units, ON/OFF cycle dates, and lab notes across devices.

At a Glance · 2026 FDA / 503A / WADA / Evidence Profile

Research / Non-FDATier 3 — Translational Animal & Clinical Obs
Pharmacological Class
Truncated 67-AA Local Somatomedin C Analog (DES(1-3)IGF-1 · Low IGFBP Affinity)
Administration Route
Under-the-skin injection (Subcutaneous peritendinous or shallow intramuscular)
2026 FDA & 503A Status
Unapproved investigational compound in the US; not listed on the FDA 503A Bulk Drug Substances positive list. Available for laboratory research with third-party HPLC + LC-MS COA verification.
WADA Sport Status
Strictly Prohibited at All Times — WADA Section S2.2 (Peptide Hormones, Growth Factors, GH Fragments, BPC-157 & Thymosin-β4)
Evidence Tier
Tier 3 — Translational Animal & Clinical Obs: Replicated mammalian preclinical models plus extensive off-label physician & community protocol tracking
What is a Peptide?

A short chain of amino acids (2-50) linked by peptide bonds. Smaller than proteins. Your body produces thousands of peptides naturally as signaling molecules that regulate everything from appetite to healing. Therapeutic peptides mimic or enhance these natural signals.

Bottom Line Up Front

IGF-1 DES (DES(1-3)IGF-1) is a truncated 67-AA variant lacking the N-terminal Gly-Pro-Glu tripeptide. It has <1% affinity for inhibitory IGF-Binding Proteins (IGFBPs), giving it ~10x local receptor potency and a short 20–30 minute half-life for targeted site-specific recovery vs 20–30 hr systemic IGF-1 LR3.

Best evidence for

Site-specific IGF-1R activation and satellite cell hyperplasia with rapid systemic clearance

Weakest evidence for

24-hour systemic elevation (where IGF-1 LR3 or GH secretagogues act longer)

Pharma equivalent

None

Studies on file

3 (0 human)

EDUCATIONAL AND RESEARCH REFERENCE ONLY — NOT MEDICAL ADVICE. IGF-1 DES (1-3) is not FDA approved for human use (unless specified above). This information does not constitute medical advice.

Overview

Endogenous 70-amino-acid IGF-1 circulates 98%+ bound to IGF-Binding Proteins (especially IGFBP-3), which blunt its immediate bioactivity. In human brain, colostrum, and mechanically stressed muscle tissue, proteases cleave off the N-terminal tripeptide (Gly-Pro-Glu) to generate DES(1-3)IGF-1 (67 amino acids). Because Glutamate at position 3 is required for IGFBP docking, IGF-1 DES bypasses IGFBPs entirely and binds with 5–10x higher functional potency to local Type 1 IGF receptors (IGF-1R)—especially in lactic-acidified tissue—before clearing the bloodstream within 20–30 minutes.

Mechanisms of Action

  • Lacks N-terminal Gly-Pro-Glu (residues 1–3), eliminating >99% of inhibitory binding to IGFBP-1 through IGFBP-6
  • Activates PI3K/Akt/mTOR and MAPK/ERK cascades at local Type 1 IGF receptors with ~10x higher functional bioactivity than native IGF-1
  • Maintains high receptor affinity in acidic microenvironments (such as injured tendons or lactate-accumulated muscle)
  • Rapid ~20–30 minute plasma half-life minimizes prolonged visceral organ exposure compared to 20–30 hour IGF-1 LR3

Common Ratios, Vial Formats & Dosing Breakdown

Researchers use different ratios depending on whether they reconstitute a pre-mixed vial or draw from separate single-compound vials.

Open in Blend Calculator
67-AA DES vs. 83-AA LR3

IGF-1 DES (Local 20–30 min Half-Life) vs. IGF-1 LR3 (Systemic 20–30 hr Half-Life)

Vial / Stack Breakdown

1 mg lyophilized vial (reconstituted with 1–2 mL BAC water or 0.6% Acetic Acid)

Typical Dosing & Syringe Draw

IGF-1 DES: 20–50 mcg bilateral local pre/post-training · IGF-1 LR3: 20–40 mcg systemic once daily

Why this ratio: Choose IGF-1 DES for site-specific repair and minimal systemic hypoglycemia window; choose IGF-1 LR3 only for full-body 24-hour signaling with strict 4-week cycling.

Research Protocols

Summaries of published research. For educational purposes only.

Protocol NameSourceDoseFrequencyDurationRouteEvidenceLinkSave
Site-Specific Local / Peritendinous Research Protocol
reported protocol
20–50 mcg total (split 10–25 mcg bilaterally into target tissue)Training or rehabilitation days only (3–5x/week immediately pre- or post-session)4 weeks on, followed by 4 weeks off to prevent IGF-1R downregulationSubcutaneous peritendinous or shallow intramuscularanimal—
Baseline & Mid-Cycle Biomarker Bloodwork Panel

GH / IGF-1 & Glycemic Sensitivity Biomarker Panel (IGF-1 DES (1-3))

Growth hormone secretagogues and somatomedin analogs directly elevate hepatic IGF-1 and can shift fasting insulin sensitivity via GH counter-regulatory signaling.

Draw fasted morning labs at Baseline (Day 0) and Mid-Cycle (Week 6–8)

Serum IGF-1 (LC/MS) + Z-Score

Day 0 + Wk 6–8

Why track at baseline: Establishes baseline somatotropic output before pituitary or local IGF-1R stimulation.

Week 6–8 check: Confirm physiological upper-quartile elevation (typically +30% to +80% above baseline) without supraphysiological overshoot (>300 ng/mL).

Fasting Insulin & HOMA-IR

Day 0 + Wk 6–8

Why track at baseline: Pituitary GH pulses promote free fatty acid mobilization, which can transiently reduce peripheral insulin sensitivity.

Week 6–8 check: Keep Fasting Insulin <6–8 uIU/mL; if elevated, enforce strict 2–3 hr pre-bed fasting before GH secretagogue administration.

HbA1c & Fasting Plasma Glucose

Day 0 + Wk 6–8

Why track at baseline: Screens for subclinical prediabetes prior to growth-factor or secretagogue exposure.

Week 6–8 check: Verify stable 90-day glycemic control (HbA1c <5.4% optimal) at Week 6–8.

hs-CRP, Prolactin & CMP

Day 0 + Wk 6–8

Why track at baseline: Checks systemic inflammation, pituitary selectivity (no off-target prolactin/cortisol rise), and hepatic/renal clearance.

Week 6–8 check: Confirm Ipamorelin/CJC/Tesamorelin selectivity with unchanged Prolactin and normal liver transaminases.

Test before and during your protocol: one baseline panel of 100+ Quest biomarkers covering the markers above, plus a mid-cycle retest. No doctor visit required.Code SPAMBASSADOR
Get baseline bloodwork at Superpower

Community Outcomes

Community Data Coming Soon

Aggregate community outcomes will be displayed here once we have more reports. Be one of the first to share your experience!

Outcomes are self-reported and unverified. They represent individual experiences and may not reflect typical results.

Important Warnings

  • •Contraindicated in anyone with active malignancy, history of cancer, or diabetic retinopathy (potent mitogenic growth factor)
  • •Can cause acute transient hypoglycemia within 15–45 minutes if administered fasted via insulin-receptor cross-talk
  • •Prohibited at all times by WADA under Section S2.2 (IGF-1 and its analogues)
  • •Limit cycles to 4 weeks maximum to avoid local IGF-1 receptor desensitization
Sourcing, Diagnostic Bloodwork & Telehealth Pathways

Where to get IGF-1 DES (1-3), baseline labs & clinician oversight.

Compare all verified suppliers ↑
50% OFF AUTO-APPLIEDFrom $0.30/mg net

Ascension Peptides (US Vials)

MZ Biolabs & SafeCert COA-verified US domestic single vials with 50% off auto-applied for new customers.

MZ Biolabs COA (Grade A)Claim 50% Off
Verified Vial SuppliersGrade A COA

SwissChems & Limitless Biotech

Same-day US domestic lyophilized vials, oral capsules, and endotoxin-screened nasal sprays (15% off Limitless w/ code PEPTIDEPROTOCOLS).

LABS & 503A CLINICS$199/yr Labs · Rx Consult

Superpower Labs & 503A Telehealth

Bloodwork, not a vial store. Get a baseline panel (100+ Quest biomarkers: metabolic, lipids, hormones, inflammation, kidney/liver) before you start a peptide protocol, then retest mid-cycle to see what actually changed.

Code:SPAMBASSADOR
FREE 1-PAGE PDF CHEAT SHEET

Peptide Reconstitution & U-100 Syringe Cheat Sheet

Printable U-100 insulin syringe draw chart for 5mg–50mg vials, plus our weekly $/mg price-drop brief.

Unsubscribe anytime.Direct PDF Download

Related Peptides

Vendor vs vendor: price per mg

Head-to-head $/mg on shared compounds. Prices verified Nov 11, 2026.

Compound vs compound: BPC-157 vs TB-500 · Tirzepatide vs Semaglutide · Retatrutide vs Tirzepatide · Wolverine Blend vs GLOW Blend · Semax vs Selank · KLOW Blend vs GLOW Blend · MOTS-c vs SS-31 · Sermorelin vs Ipamorelin · Retatrutide vs Semaglutide · Tesamorelin vs Sermorelin · All compounds $/mg →

Common questions

How many peptides are in the database?

100 compound pages, each with dosing references, reconstitution math and price per mg where a verified vendor price exists.

Where can I compare peptide prices?

Each compound page shows verified $/mg by vendor; the vendor-vs-vendor pages above compare two vendors across their shared compounds.